Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Management has been bullish recently. The company raised its guidance for the remainder of 2010 following the strong third quarter. It has also been buying back shares in droves this year and recently hiked its quarterly dividend.
EPS Increase 47%
Third quarter earnings per share for 2010 came in at 28 cents, beating the Zacks Consensus Estimate by 4 cents. It was a 47% increase over the same quarter in 2009.
Total revenue was up 22% year-over-year, driven in large part by an 8.0% increase in gross written premiums.
Selling, general, and administrative expenses dropped 29% as the company was able to leverage its fixed costs. Meanwhile, net operating income grew a stellar 25%.
Guidance Raised
The company raised guidance for both 2010 and 2011 following the strong third quarter. Management expects 2010 EPS between $1.03 to $1.05 per share, up from previous guidance of $0.90 to $1.00.
The Zacks Consensus Estimate is right in the middle of guidance at $1.04.
The company expects 2011 EPS between $1.00 and $1.10. The Zacks Consensus Estimate is again right in the middle at $1.05.
Meadowbrook has beaten the Zacks Consensus Estimate in 9 of the last 10 quarters, as seen in the Price & EPS Surprise chart:
Rewarding Shareholders
Meadowbrook repurchased approximately 323,000 shares in the quarter and has spent over $20 million total year-to-date buying back about 2.5 million shares. There is an additional 2.5 million shares left under its current Share Repurchase Plan.
The company also recently hiked its quarterly dividend from 3 cent per share to 4 cents. It currently yields 1.6%
Valuation
Valuation still looks attractive for this specialty insurance company. The forward P/E is just 9.4x, a discount to the industry average of 11.9x. It is also trading below book value at 0.9x.
Read the September 8 article here.
Last Week's Growth & Income Zacks Rank Buy Stocks:
Tiffany & Co. (TIF) is seeing strong momentum heading into the all-important holiday shopping season. The company recently reported excellent third quarter results as same-store sales jumped 7%. Read the full article.
Ruddick Corporation (RDK) recently delivered its sixth consecutive positive earnings surprise as business continues to improve. The stock has risen almost 50% year-to-date, but because estimates continue to rise too, valuation remains in check. Read the full article.
IDEX Corporation (IEX) recently delivered its sixth consecutive positive earnings surprise on strong sales growth and an expanding operating margin. The company continues to see strength across each business segment as the global economic recovery gains traction. Read the full article.
Ituran Location & Control Ltd. (ITRN) has a large presence in Brazil and will benefit from a new rule requiring all new vehicles to have a GPS-based tracking system installed. This presents a huge opportunity considering that the country is adding 2.5 million new cars per year. Read the full article.
Todd Bunton is the Growth & Income Stock Strategist for Zacks.com.
Read the full reports :
Snapshot Report on MIG